Showing results (401-410 of 511) with videos related to

Sort By:
Pageof 52
American Journal of Preventive Medicine|August 25, 2018
Violence-Related Disparities Experienced by Black Youth and Young Adults: Opportunities for PreventionKameron J Sheats, Shalon M Irving, Jim A Mercy, et al.
Expert Opinion on Drug Safety|July 21, 2022
Safety and tolerability of spesolimab in patients with ulcerative colitisMarc Ferrante, Peter M Irving, Christian P Selinger, et al.
Inflammatory Bowel Diseases|November 11, 2023
Adalimumab Drug Levels at Secondary Loss of Response Do Not Predict Response to Dose-intensification in Crohn's Disease: A Retrospective, International Multicenter StudyRobert D Little, Adrian Swaine, Rebecca Reynolds, et al.
Alimentary Pharmacology & Therapeutics|June 8, 2020
Therapeutic thresholds for golimumab serum concentrations during induction and maintenance therapy in ulcerative colitis: results from the GO-LEVEL studyMark A Samaan, Georgina Cunningham, Aravind Gokul Tamilarasan, et al.
Diabetic Medicine : a Journal of the British Diabetic Association|December 3, 2008
Unrecognized glucose intolerance is not associated with depression. Screening for Impaired Glucose Tolerance study 3 (SIGT 3)M K Rhee, D Musselman, D C Ziemer, et al.
Infection and Immunity|May 24, 2005
Human immune response to a plague vaccine comprising recombinant F1 and V antigensE D Williamson, H C Flick-Smith, C Lebutt, et al.
Crohn'S & Colitis 360|July 11, 2026
Mirikizumab is equally effective in ustekinumab-exposed and ustekinumab-naïve patients with UC: a multicenter real-world cohortMohmmed Tauseef Sharip, Dharmaraj Durai, Eva Vayreda, et al.
United European Gastroenterology Journal|June 8, 2017
Thioguanine in inflammatory bowel disease: Long-term efficacy and safetyMark G Ward, Kamal V Patel, Viraj C Kariyawasam, et al.
The Journal of Physiology|February 8, 2012
Mechanics of myosin function in white muscle fibres of the dogfish, Scyliorhinus caniculaS Park-Holohan, M Linari, M Reconditi, et al.
Inflammatory Bowel Diseases|March 4, 2026
Mirikizumab four-year sustained and durable efficacy and safety in ulcerative colitis: Final findings from the LUCENT-3 open-label extension studyBruce E Sands, David B Clemow, Geert D'Haens, et al.
Pageof 52